{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:25:20Z","timestamp":1772011520813,"version":"3.50.1"},"reference-count":10,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Allergy\ufffdRhinol (Providence)"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p> Atopic dermatitis (AD, eczema) is familial chronic inflammatory skin disease of complex etiology and increasing prevalence. Dupilumab is an IL-4 receptor subunit alpha (IL-4R\u03b1) antagonist that is the first Food and Drug Administration-approved biological therapy for moderate-to-severe adult AD inadequately controlled with topical therapies. Adverse effects reported in the literature include injection site reactions, conjunctivitis, headache, and nasopharyngitis. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p> We report the first cases of hyperhidrosis and bromhidrosis as side effects from dupilumab (Dupixent\u00ae) for the treatment of AD. <\/jats:p><\/jats:sec><jats:sec><jats:title>Case Reports<\/jats:title><jats:p> Case 1 is a 20-year-old woman with controlled allergic rhinitis and severe AD reported axillary hyperhidrosis with bromhidrosis, comparable to sweat from high-intensity exercise, with no relief from several different over-the-counter antiperspirants. Case 2 is a 61-year-old woman with history of chronic asthma, allergic contact dermatitis, allergic rhinitis, and AD noticed markedly increased sweating with bromhidrosis that was reminiscent of her menopausal symptomology, about 3 months after initiating dupilimab. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p> Traditional immunosuppressive agents and corticosteroids have limited efficacy, numerous side effects, and increased risk of infection. The safety profile and efficacy of the newly approved IL-4R\u03b1 antagonist dupilumab may be favorable to oral immunosuppressants, but its use remains limited to severe recalcitrant cases, due to financial implications and lack of long-term safety data and comparative head-to-head trials. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> We report improved outcomes with dupilumab, in addition to unpublished cases of bromhidrosis and hyperhidrosis in 2 patients with AD. This report of additional complications may inspire further clinical research and assist clinicians in considering the option of dupilumab for uncontrolled AD, despite aggressive traditional treatment. <\/jats:p><\/jats:sec>","DOI":"10.1177\/2152656720927703","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:49:30Z","timestamp":1589971770000},"page":"215265672092770","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Something to Sweat About: Two Cases of Dupilumab-Induced Hyperhidrosis and Bromhidrosis"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-8279","authenticated-orcid":false,"given":"Marija","family":"Rowane","sequence":"first","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reimus","family":"Valencia","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care, University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Schend","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care, University Hospitals Cleveland Medical Center, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care, University Hospitals Cleveland Medical Center, Cleveland, Ohio"},{"name":"Allergy Immunology Associates, Inc., Mayfield Heights, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Hostoffer","sequence":"additional","affiliation":[{"name":"Department of Pulmonary & Critical Care, University Hospitals Cleveland Medical Center, Cleveland, Ohio"},{"name":"Allergy Immunology Associates, Inc., Mayfield Heights, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"bibr1-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"bibr2-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.672"},{"key":"bibr3-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318773686"},{"key":"bibr4-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.031"},{"key":"bibr5-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"bibr6-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.03.007"},{"key":"bibr7-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2018.06.003"},{"key":"bibr8-2152656720927703","doi-asserted-by":"publisher","DOI":"10.4103\/ds.ds_48_18"},{"key":"bibr9-2152656720927703","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"bibr10-2152656720927703","first-page":"79","volume":"13","author":"Albader SS","year":"2019","journal-title":"Biologics"}],"container-title":["Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2152656720927703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2152656720927703","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2152656720927703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:29:58Z","timestamp":1740976198000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/2152656720927703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":10,"alternative-id":["10.1177\/2152656720927703"],"URL":"https:\/\/doi.org\/10.1177\/2152656720927703","relation":{},"ISSN":["2152-6567","2152-6567"],"issn-type":[{"value":"2152-6567","type":"print"},{"value":"2152-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}